Clinical Trials
177 trialsA Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
MOMENTUM-1
RTOG Foundation, Inc.
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
NEURO-SUTURE
Medical University of Warsaw
MEN-301
NX Development Corp
SRS-AIM
University of California, San Francisco
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
MIRAGE
Istituto Oncologico Veneto IRCCS
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Heron Neutron Medical Corp.
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NRG Oncology
INTUITT-NF2
Massachusetts General Hospital
EViDENCE-BT
University of Zurich
NK Cell Therapy for Malignant Solid Brain Tumors
Peking University Third Hospital
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Jazz Pharmaceuticals
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
Massachusetts General Hospital
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
LUPARPED
Fundación de investigación HM
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Vanderbilt-Ingram Cancer Center
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
MOLI
University Hospital Heidelberg
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Weill Medical College of Cornell University
PIVIM
Hospices Civils de Lyon
SIMPLIF-AI
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
HiPPI
Emory University
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
Shengjing Hospital
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
DEX-NEURO
University of Malaya
BIOLIMEN-1
University Hospital, Montpellier
Evaluation of the CONVIVO System
Dartmouth-Hitchcock Medical Center
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
A Study of ONC201 for Refractory Meningioma
University of Nebraska
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
Thomas Jefferson University
Robot-Assisted Neurovascular Intervention
Navigantis Inc.
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
DOMINO-START
Weill Medical College of Cornell University
HOBSCOTCH-CA
Dartmouth-Hitchcock Medical Center
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center